Trulicity and Ozempic are two commonly prescribed medications for managing type 2 diabetes. Both belong to a class of drugs called GLP-1 receptor agonists and are known for improving blood sugar control while aiding in weight management. However, understanding how they differ is essential for selecting the option that best suits individual needs.
Each medication has unique features, from dosing schedules to potential side effects, and these differences can influence treatment outcomes. Deciding between them requires a clear comparison to weigh the benefits and considerations of each.
This article will compare these two drugs in terms of effectiveness, safety, and other practical factors to help patients make an informed decision about their treatment plan.
Efficacy of Trulicity & Ozempic
A head-to-head study (SUSTAIN 7) compared Ozempic and Trulicity’s for their effectiveness and safety in managing type 2 diabetes. The study lasted 40 weeks and included multiple centers across different countries.
The study primarily focused on how much each medication lowered participants’ A1C levels (a key measure of blood glucose control) from the start to the end of the study. Secondary goals included changes in body weight and the percentage of patients achieving an A1C level below 7%, which is a common diabetes target.
Here’s a summary of the study’s outcomes:
Comparing Trulicity & Ozempic For Blood Sugar Control
Ozempic delivered better results in A1C management compared to Trulicity. Specifically, the A1C reductions at week 40 are as follows:
| Dose (Ozempic vs Trulicity) | Ozempic | Trulicity |
|---|---|---|
| Lower Dose (0.5 mg vs 0.75 mg) | 1.4% | 1.1% |
| Higher Dose (1 mg vs 1.5 mg) | 1.6% | 1.3% |
The results demonstrate that both doses of Ozempic showed superior A1C reductions compared to their respective Trulicity doses. Additionally, a higher percentage of patients on Ozempic achieved an A1C level below 7% compared to those on Trulicity.
At the lower doses, 65% of patients on Ozempic 0.5 mg reached the target, compared to 51% on Trulicity 0.75 mg. At the higher doses, 73% of patients on Ozempic 1 mg achieved this goal versus 63% on Trulicity 1.5 mg.
These results highlight Ozempic’s superior ability to help patients meet blood glucose targets.
Comparing Trulicity & Ozempic For Weight Loss
Despite not being primarily intended for weight loss, Ozempic and Trulicity can influence weight, which is important in managing type 2 diabetes. Evaluating how these medications affect both blood sugar and body weight is essential.
In the SUSTAIN trial, Ozempic led to greater weight loss than Trulicity at both dose levels, as shown below:
| Dose (Ozempic vs Trulicity) | Weight Change with Ozempic (lbs) | Weight Change with Trulicity (lbs) |
|---|---|---|
| Lower Dose (0.5 mg vs 0.75 mg) | 9.3 | 4.6 |
| Higher Dose (1 mg vs 1.5 mg) | 12.8 | 6.2 |
Currently, no head-to-head data are available comparing Ozempic 2.0 mg with Trulicity 3.0 mg or 4.5 mg. However, an indirect treatment comparison published in 2022 demonstrated that the highest dose of Ozempic achieved greater reductions in A1C levels and body weight. Additionally, patients on Ozempic were 2.23 times and 1.58 times more likely to achieve an A1C level below 7.0% compared to Trulicity 3.0 mg and 4.5 mg, respectively.
Another indirect comparison evaluated Ozempic 1.0 mg against Trulicity 3.0 mg and 4.5 mg and showed similar results. Ozempic led to greater improvements in A1C levels and weight.
Comparing Trulicity & Ozempic in Reducing the Risk of MACE
Both Ozempic and Trulicity are approved for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease. To compare their efficacy, researchers conducted an indirect analysis of Ozempic (0.5 mg and 1 mg) and Trulicity (1.5 mg). Ozempic showed a greater reduction in three-point MACE, which includes:
-
- Cardiovascular death
- Non-fatal myocardial infarction (heart attack)
- Non-fatal stroke
However, this difference did not reach statistical significance, which means that the observed difference might be due to chance rather than a true effect.
Mechanism of Action
Ozempic, which contains semaglutide, and Trulicity, which contains dulaglutide, work by mimicking a natural hormone in the body called GLP-1. This hormone helps regulate glucose levels and appetite. Both medications attach to GLP-1 receptors, which are found in areas like the pancreas, stomach, and brain, to help the body manage blood sugar more effectively.
In the pancreas, they help release insulin, a hormone that lowers blood sugar, but only when blood sugar levels are high to reduce the risk of dangerously low sugar levels. At the same time, they signal the pancreas to release less glucagon, another hormone that raises blood sugar, so the liver doesn’t produce too much sugar.
These medications also slow down how quickly food leaves the stomach, which helps prevent blood sugar spikes after meals. Lastly, they work in the brain to reduce appetite, indirectly supporting glucose control by reducing caloric intake.
They work in very similar ways, but their difference lies in their structure and how they are processed by the body. Ozempic has a higher bioavailability, longer half-life, and stronger binding to albumin. These factors work together to keep the medication active in the body for a longer period.
Dosing Schedule of Trulicity vs Ozempic
Here is a comparison of the dosing schedules for Ozempic and Trulicity in adults:
| Medication | Starting Dose | Titration Dose | Maximum Dose | |||
| Month 1 | Month 2 | Month 3 | Month 4 | |||
| Ozempic (semaglutide) | 0.25 mg once weekly | 0.25 mg per week | 0.5 mg per week | 0.5-1.0 mg per week | 1.0-2.0 mg per week | 2.0 mg once weekly |
| Trulicity (dulaglutide) | 0.75 mg once weekly | 0.75 mg per week | 1.5 mg per week | 1.5-3.0 mg per week | 3.0-4.5 mg per week | 4.5 mg once weekly |
For pediatric patients, Trulicity should be initiated at 0.75 mg once weekly. If additional glycemic control is needed, the dose may be increased to 1.5 mg once weekly after at least 4 weeks. This is the maximum approved dose for pediatric use.
Wrap-up
Both medications belong to the same drug class and offer proven benefits in blood sugar control and cardiovascular risk reduction. However, the findings from studies like SUSTAIN 7 indicate that Ozempic outperforms Trulicity in both A1C reduction and weight loss across various dosage levels.
Patients should also weigh the side effect profiles of these medications, as gastrointestinal issues are common with both, though slightly more pronounced with Ozempic. Additionally, Ozempic’s longer half-life and higher bioavailability contribute to its effectiveness, while Trulicity’s pediatric approval offers advantages for younger individuals with diabetes. Cost is another factor to consider, though their prices are nearly identical.
Selecting the right medication requires a personalized approach. Collaboration with a healthcare provider ensures that factors such as medical history, treatment goals, and affordability are fully considered.
What to Read Next:
If you’re looking for more information, you can also explore the following articles:
These resources will help you make confident decisions about your diabetes care.
Frequently Asked Questions
Related Articles
Sources
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275–286. https://doi.org/10.1016/s2213-8587(18)30024-x
Lingvay, I., Bauer, R., Baker-Knight, J., Lawson, J., & Pratley, R. (2021). An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of Clinical Endocrinology & Metabolism, 107(5), 1461–1469. https://doi.org/10.1210/clinem/dgab905
Pratley, R. E., Catarig, A., Lingvay, I., Viljoen, A., Paine, A., Lawson, J., Chubb, B., Gorst?Rasmussen, A., & Miresashvili, N. (2021). An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obesity and Metabolism, 23(11), 2513–2520. https://doi.org/10.1111/dom.14497
Evans, L. M., Mellbin, L., Johansen, P., Lawson, J., Paine, A., & Sandberg, A. (2021). A population?adjusted indirect comparison of cardiovascular benefits of once?weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinology Diabetes & Metabolism, 4(3). https://doi.org/10.1002/edm2.259
Eli Lilly and Company. (2024). Highlights Of Prescribing Information of Trulicity. Retrieved from https://pi.lilly.com/us/trulicity-uspi.pdf
Novo Nordisk. (2024). Highlights Of Prescribing Information of Ozempic. Retrieved from https://www.novo-pi.com/ozempic.pdf




